Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Angioplasty, stenting, atherectomy, intravascular imaging. Main billing specialty: interventional cardiology.
Medicare fee-for-service coronary intervention (PCI) cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (254 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 398 | 18,276−5%/yr | −5%/yr | 6.51.2× | 5% | 19,500 in 2030+1.1%/yr |
| California | 390 | 17,678−4.1%/yr | −4.1%/yr | 4.30.8× | 0% | 19,700 in 2030+1.8%/yr |
| Texas | 422 | 17,591−6%/yr | −6%/yr | 6.61.2× | 5% | 20,600 in 2030+2.7%/yr |
| New York | 245 | 13,378−4.1%/yr | −4.1%/yr | 5.91.1× | 0% | 13,900 in 2030+0.6%/yr |
| Illinois | 214 | 9,057−5.7%/yr | −5.7%/yr | 5.51.0× | 1% | 9,710 in 2030+1.2%/yr |
| Ohio | 211 | 8,829−5.6%/yr | −5.6%/yr | 6.41.2× | 0% | 9,250 in 2030+0.8%/yr |
| Pennsylvania | 224 | 8,394−5.9%/yr | −5.9%/yr | 5.00.9× | 1% | 8,320 in 2030−0.1%/yr |
| Georgia | 147 | 6,267−8%/yr | −8%/yr | 5.81.1× | 0% | 7,490 in 2030+3%/yr |
| Michigan | 162 | 6,045−10%/yr | −10%/yr | 5.61.0× | 1% | 6,100 in 2030+0.2%/yr |
| New Jersey | 172 | 6,009−4.6%/yr | −4.6%/yr | 4.90.9× | 0% | 7,900 in 2030+4.7%/yr |
| Arizona | 142 | 5,873−3.4%/yr | −3.4%/yr | 6.51.2× | 17% | 6,410 in 2030+1.5%/yr |
| North Carolina | 124 | 5,638−9.6%/yr | −9.6%/yr | 4.60.8× | 0% | 6,040 in 2030+1.2%/yr |
| Virginia | 130 | 5,552−4.5%/yr | −4.5%/yr | 4.60.8× | 1% | 6,460 in 2030+2.6%/yr |
| Missouri | 136 | 5,507−8.8%/yr | −8.8%/yr | 7.21.3× | 0% | 5,950 in 2030+1.3%/yr |
| Indiana | 142 | 5,468−7.3%/yr | −7.3%/yr | 6.41.2× | 0% | 5,370 in 2030−0.3%/yr |
| Tennessee | 134 | 5,286−10%/yr | −10%/yr | 6.11.1× | 0% | 5,620 in 2030+1%/yr |
| Washington | 110 | 4,758−3.4%/yr | −3.4%/yr | 5.10.9× | 0% | 4,980 in 2030+0.7%/yr |
| Arkansas | 86 | 4,691−7.9%/yr | −7.9%/yr | 10.41.9× | 2% | 4,440 in 2030−0.9%/yr |
| Massachusetts | 103 | 4,352−4.8%/yr | −4.8%/yr | 4.00.7× | 0% | 4,790 in 2030+1.6%/yr |
| South Carolina | 103 | 4,333−4.9%/yr | −4.9%/yr | 5.31.0× | 0% | 4,970 in 2030+2.3%/yr |
| Oklahoma | 89 | 4,003−9.8%/yr | −9.8%/yr | 7.01.3× | 3% | 3,940 in 2030−0.2%/yr |
| Kentucky | 96 | 3,828−8.3%/yr | −8.3%/yr | 6.71.2× | 0% | 3,340 in 2030−2.2%/yr |
| Louisiana | 80 | 3,628−10%/yr | −10%/yr | 7.11.3× | 5% | 3,290 in 2030−1.6%/yr |
| Wisconsin | 82 | 3,280−8.3%/yr | −8.3%/yr | 4.60.8× | 0% | 3,530 in 2030+1.2%/yr |
| Alabama | 83 | 3,251−13%/yr | −13%/yr | 5.81.1× | 0% | 3,010 in 2030−1.3%/yr |
| Maryland | 71 | 3,197−5.6%/yr | −5.6%/yr | 3.30.6× | 0% | 4,090 in 2030+4.2%/yr |
| Minnesota | 82 | 3,062−7.9%/yr | −7.9%/yr | 5.31.0× | 0% | 3,640 in 2030+2.9%/yr |
| Mississippi | 69 | 2,933−9.1%/yr | −9.1%/yr | 6.61.2× | 6% | 2,780 in 2030−0.9%/yr |
| Iowa | 58 | 2,810−5.2%/yr | −5.2%/yr | 5.51.0× | 3% | 2,590 in 2030−1.4%/yr |
| Colorado | 63 | 2,688−3.7%/yr | −3.7%/yr | 4.50.8× | 1% | 3,050 in 2030+2.1%/yr |
| Kansas | 59 | 2,634−7.4%/yr | −7.4%/yr | 5.71.0× | 6% | 3,030 in 2030+2.3%/yr |
| Nevada | 41 | 1,817−3%/yr | −3%/yr | 5.10.9× | 0% | 1,970 in 2030+1.4%/yr |
| Oregon | 40 | 1,758−7.7%/yr | −7.7%/yr | 3.40.6× | 2% | 1,840 in 2030+0.7%/yr |
| West Virginia | 36 | 1,595−10%/yr | −10%/yr | 6.21.1× | 0% | 1,560 in 2030−0.4%/yr |
| Utah | 33 | 1,541−5.4%/yr | −5.4%/yr | 5.71.0× | 0% | 1,540 in 20300%/yr |
| Connecticut | 40 | 1,475−9.6%/yr | −9.6%/yr | 3.60.7× | 0% | 1,300 in 2030−2.1%/yr |
| Nebraska | 31 | 1,417−6.6%/yr | −6.6%/yr | 4.80.9× | 2% | 1,490 in 2030+0.8%/yr |
| South Dakota | 17 | 1,290−7.2%/yr | −7.2%/yr | 8.71.6× | 0% | 1,620 in 2030+3.9%/yr |
| New Hampshire | 25 | 1,180−3.6%/yr | −3.6%/yr | 4.50.8× | 0% | 1,640 in 2030+5.7%/yr |
| Montana | 18 | 1,037−8.8%/yr | −8.8%/yr | 4.90.9× | 0% | 1,380 in 2030+4.8%/yr |
| New Mexico | 18 | 1,021−9%/yr | −9%/yr | 3.60.7× | 0% | 1,030 in 2030+0.2%/yr |
| North Dakota | 17 | 1,001−4.7%/yr | −4.7%/yr | 8.81.6× | 0% | 1,160 in 2030+2.5%/yr |
| Idaho | 23 | 908−8.2%/yr | −8.2%/yr | 3.70.7× | 0% | 1,170 in 2030+4.3%/yr |
| Delaware | 21 | 734−9.5%/yr | −9.5%/yr | 3.80.7× | 0% | 780 in 2030+0.9%/yr |
| Rhode Island | 15 | 674−3.8%/yr | −3.8%/yr | 5.81.1× | 0% | 740 in 2030+1.6%/yr |
| Maine | 17 | 602−13%/yr | −13%/yr | 3.00.6× | 0% | 600 in 20300%/yr |
| Alaska | 9 | 512−4.6%/yr | −4.6%/yr | 4.20.8× | 0% | 550 in 2030+1.2%/yr |
| District of Columbia | 8 | 452−5.7%/yr | −5.7%/yr | 6.31.1× | 0% | 550 in 2030+3.3%/yr |
| Vermont | 8 | 437−6.6%/yr | −6.6%/yr | 3.40.6× | 0% | 790 in 2030+10%/yr |
| Hawaii | 9 | 344−2.3%/yr | −2.3%/yr | 2.10.4× | 0% | 570 in 2030+8.7%/yr |
| Wyoming | 3 | 218−9.7%/yr | −9.7%/yr | 1.90.3× | 0% | 210 in 2030−0.6%/yr |
Professional codes (what the surgeon bills): CPT 92920, 92928, 92933, 92937, 92941, 92943; the hospital bills MS-DRG 246, 247, 248, 249, 321, 322, 323, 324, 325, 318, 359, 360.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 673 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 26 companies. The most active:
Product codes: LOX (catheters, transluminal coronary angioplasty, percutaneous), MAF (stent, coronary), NIQ (coronary drug-eluting stent). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
The 10 busiest do 11% of the cases CMS names in Florida; 226 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Structural heart (TAVR, TEER) | 2,849 | 63,491+3.8%/yr | +3.8%/yr | 90,800 in 2030+6.2%/yr |
| Mechanical circulatory support | 56 | 17,228−4.4%/yr | −4.4%/yr | 19,300 in 2030+1.9%/yr |
| PFO & septal closure | 10 | 1,097+2.2%/yr | +2.2%/yr | 1,130 in 2030+0.5%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 14 companies reported engagement with surgeons in the covered states worth $16M in consulting, speaking, meals and travel tied to these products, about $3,073 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 38 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.